Mirum’s Zilurgisertib Delivers Strong Phase 2 Cohort 1 Data In FOP Ahead Of FDA Decision

Research on Zilurgisertib for FOP demonstrates significant statistical advantages in patient outcomes, particularly in reducing heterotopic ossification. Key findings indicate a 50% decrease in complications at weekly assessments. Further analysis confirms the compound’s efficacy in long-term management, positioning it as a critical therapeutic candidate for future clinical trials.>

Source link